Abstract: The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.

Abstract: The present invention relates to pharmaceutical compositions comprising Avian Paramyxovirus (APMV) for use in the treatment of a tumor in a mammal.

Abstract: The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.

Abstract: The present invention relates to pharmaceutical compositions comprising Avian Paramyxovirus (APMV) for use in the treatment of a tumor in a mammal.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.